No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.

Journal article

Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.

Authors: van Vugt, M; Ezzet, F; Nosten, F; Gathmann, I; Wilairatana, P

• Publication status: Published
• Journal: American journal of tropical medicine and hygiene
• Volume: 61
• Issue: 6
• Pages: 964-967
• Publication date: 1999-12-01
• EISSN: 1476-1645
• ISSN: 0002-9637
• Language: English
• Keywords: Adolescent; Heart; Humans; Antimalarials; Adult; Middle Aged; Sesquiterpenes; Female; Drug Therapy, Combination; Fluorenes; Male; Malaria, Falciparum; Electrocardiography; Child; Artemisinins; Child, Preschool; Ethanolamines